Adynatrace Q1 2026 Investor Presentation August 6, 2025 Legal Disclaimer This presentation consists of theses slides and the associated remarks and comments, which are related and intended to be presented and understood together. Pease refer of certain terms. Cautionary Language Concerning Forward-Looking Statements This presentation inducles sertain "forward-lobing statements" within the maning of the Printer Securities Litication Reform At of 1299, induling statements regarding Dyn and current be withs th ...

Investor Presentation: Half-year 2025 Safe harbour statements NOTE REGARDING FORWARD-LOOKING STATEMENTS: CERTAIN STATEMENTS AND INDICATIVE PROJECTIONS (WHICH MAY INCLUDE MODELLED LOSS SCENARIOS) MADE IN THIS PRESENTATION OR OTHERWISE THAT ARE NOT BASED ON CURRENT OR HISTORICAL FACTS ARE FORWARD-LOOKING IN NATURE INCLUDING, WITHOUT LIMITATION, STATEMENTS CONTAINING THE WORDS "BELIEVES", "AIMS", "ANTICIPATES", "PLANS", "PROJECTS", "FORECASTS", "GUIDANCE", "INTENDS", "EXPECTS", "ESTIMATES", "PREDICTS", "MAY", ...

Financial Performance - Net earnings per diluted share decreased by 642% from $310 in 2Q24 to $111 in 2Q25[9] - Adjusted earnings per diluted share decreased by 27% from $183 in 2Q24 to $178 in 2Q25[9] - Adjusted earnings per diluted share excluding foreign currency impact decreased by 55% from $183 in 2Q24 to $173 in 2Q25[9] - U S GAAP ROE decreased from 283% in 2Q24 to 90% in 2Q25[12] - Adjusted ROE decreased from 143% in 2Q24 to 137% in 2Q25[12] - Adjusted ROE excluding foreign currency remeasurement decreased from 175% in 2Q24 to 164% in 2Q25[12] Business Segment Performance - Aflac Japan's premium persistency remained relatively stable at 933% in 2Q24 and 937% in 2Q25[15] - Aflac Japan's QTD actual operating ratios for 2Q25 include a benefit ratio of 665%, an expense ratio of 206%, and a pretax profit margin of 320%[18] - Aflac U S's persistency remained relatively stable at 787% in 2Q24 and 792% in 2Q25[20] - Aflac U S's QTD actual operating ratios for 2Q25 include a benefit ratio of 473%, an expense ratio of 363%, and a pretax profit margin of 225%[22] Capital Management - The company's estimated regulatory ESR in Japan is >240% and the combined RBC ratio in the U S is >600% as of June 30, 2025[24] - The company's adjusted leverage ratio increased from 195% in 2Q24 to 225% in 2Q25[29]

Financial Performance - Lantheus' Q2 2025 revenues were $378 million, a decrease of 4.1% compared to Q2 2024[15, 52] - Adjusted EPS for Q2 2025 was $1.57, a decrease of 12.8% year-over-year[15, 52] - Radiopharmaceutical Oncology sales were $250.6 million, down 8.3% year-over-year, but with a 4% sequential volume increase[52] - Precision Diagnostics sales were $115.8 million, up 3.3% year-over-year, driven by DEFINITY sales growth of 7.5%[52] - Strategic Partnerships sales were $11.6 million, up 32.8% year-over-year[52] Financial Position - Cash provided by operations increased to $87.1 million in Q2 2025 from $84.7 million in Q2 2024[55] - Free cash flow for Q2 2025 was $79.1 million[58] - Lantheus has $695.6 million in cash on hand and $750 million available in revolving credit[58] Guidance - Updated FY 2025 revenue guidance is $1.475 billion - $1.51 billion[61] - Updated FY 2025 adjusted fully diluted EPS guidance is $5.50 - $5.70[61] Strategic Initiatives - Lantheus anticipates four key product launches in the next 18 months: MK-6240, OCTEVY, PNT2003, and a new PSMA PET formulation[20] - The company has a board authorization for a new $400 million stock repurchase program[59]

Financial Performance - Uber's Q2 2025 revenue reached $12651 million, representing an 18% increase year-over-year[54] - Adjusted EBITDA for Q2 2025 was $2119 million, a 35% increase year-over-year[57] - Mobility gross bookings grew to $23762 million in Q2 2025, an 18% increase in constant currency year-over-year[63] - Delivery gross bookings increased to $21734 million in Q2 2025, reflecting a 20% growth in constant currency year-over-year[70] - Freight revenue remained relatively stable at $1261 million in Q2 2025, showing a (1%) change in constant currency year-over-year[75] Operational Metrics - Monthly Active Platform Consumers (MAPCs) increased by 15% year-over-year, reaching 180 million in Q2 2025[42] - Total trips grew by 18% year-over-year to 3268 million in Q2 2025[44] - Monthly trips per MAPC (Frequency) increased by 2% year-over-year to 61 in Q2 2025[43] Strategic Initiatives - Uber One membership program has 36 million members and accounts for over 40% of combined Delivery & Mobility bookings[31, 32] - Uber is expanding its AV technology commercialization, with deployments in 12 cities across 3 countries and plans for ~5 additional cities in 2025[35, 36]

2Q 2025 Financial Highlights - Adjusted net revenue reached $2.4 billion, reflecting a growth of 2%, or 5% on a constant currency basis excluding dispositions[11] - Adjusted operating margin was 44.6%, an increase of 130 basis points, or 110 basis points excluding dispositions[11] - Adjusted EPS stood at $3.10, representing an 11% increase, or 11% on a constant currency basis[11] - The company generated strong adjusted free cash flow with a 108% conversion rate[10] Segment Performance - Merchant Solutions reported adjusted net revenue of $1.8 billion, up 1%, or 5.5% on a constant currency basis excluding dispositions, with an adjusted operating margin of 50.1%, up 130 basis points[13] - Issuer Solutions reported adjusted net revenue of $547 million, up 4%, or 3.5% on a constant currency basis, with an adjusted operating margin of 48.7%, up 190 basis points[13] Key Metrics - New partners increased by 15% for merchants and 28% for issuers[15] - Traditional accounts on file growth was 9%[15] - Bookings growth was 13%[15] 2025 Outlook - The company anticipates adjusted net revenue growth of 5% to 6% on a constant currency basis excluding dispositions[17] - Adjusted operating margin expansion is expected to be greater than 50 basis points excluding dispositions[17] - Adjusted EPS growth is projected to be at the high end of 10% to 11% on a constant currency basis[17] - Adjusted free cash flow conversion is expected to be 90%+[17] Strategic Initiatives - The company is entering into a $500 million accelerated share repurchase plan in connection with the Payroll divestiture[10] - Capital return expectations for 2025-2027 have been raised to $7.5 billion, excluding returns associated with asset dispositions[10] - The expected annual run-rate operating income benefit from operational transformation has been increased to $650 million[10]

Q3 2025 Performance - Underlying sales growth was 3%[13], impacted by reduced pricing actions due to improved tariff exposure[13] - Adjusted EPS of $1.52 met the top end of guidance[13] - Free cash flow generation exceeded expectations, yielding a 21.3% margin[11] Orders and Demand - Underlying orders grew by 4%[13]; Test & Measurement orders increased by 16%[13] - Strong demand continues in process and hybrid markets, with discrete markets showing recovery[10] - Industrial software saw strong demand, with Annual Contract Value (ACV) at $1.5 billion, up 10% year-over-year[10] Q4 2025 Guidance - Expects underlying sales growth between 5% and 6%[11], driven by Test & Measurement recovery and automation investments[11] - Anticipates an adjusted segment EBITA margin of approximately 27%[11], higher than previously expected due to lower tariff exposure[11] - Projects adjusted EPS of $1.58 to $1.62, representing a 7% to 10% year-over-year increase[11] Tariff Mitigation - Reduced tariff exposure by approximately $210 million annualized[21], expecting full offset[21] - Gross tariffs are estimated at $455 million annualized[22], with mitigations of approximately $130 million[22] through price and supply chain actions[22] Full Year 2025 Guidance - Free Cash Flow raised to approximately $3.2 billion[32], with an ~18% margin[32] - Price is now expected to contribute ~2.5 percentage points due to the improved tariff environment[32]

Winning today Creating tomorrow Results for the Six Months Ended 27 June 2025 6 August 2025 Forward looking statements This document contains statements, estimates or projections that constitute "forward-looking statements" concerning the financial condition, performance, results, guidance and outlook, dividends, consequences of mergers, acquisitions, joint ventures, divestitures, strategy and objectives of Coca-Cola Europacific Partners plc and its subsidiaries (together CCEP or the Group). Generally, the ...

Performance Highlights Quarter ended 30th June 2025 P O W E R F I N A N C E C O R P O R A T I O N L T D . A M a h a r a t n a P S U Funding for a brighter Tomorrow Table of Contents PFC AT A GLANCE Powering Nation's Development CONSOLIDATED PERFORMANCE III. IV. STANDLAONE PERFORMANCE ESG AT PFC Page • 2 I. II. PFC Group structure PFC Financing Progress Consolidated highlights Key Consolidated Financials Highlights Earning Update Asset quality Operational Performance Shareholder Outlook ESG Vision ESG journe ...

Financial Performance & Strategic Aspirations - Novo Nordisk achieved sales growth of 18% (CER) in the first six months of 2025, with operating profit growth of 29% (CER)[11] - Obesity care sales reached DKK 38.8 billion, a 58% increase at CER, highlighting the strong performance in this therapeutic area[11] - Rare disease sales increased by 15% at CER, reaching DKK 9.5 billion[11] - The company returned DKK 36.5 billion to shareholders, demonstrating a commitment to attractive capital allocation[11] Market Dynamics & Key Products - In the US, the branded anti-obesity medication market experienced growth exceeding 160%[28] - International Operations saw sales growth of 19%, driven by GLP-1 Diabetes and Obesity care[33] - Total GLP-1 class market share in International Operations reached 71%[36] - Global diabetes and obesity unmet need is significant, with less than 1% of people with obesity globally treated with branded AOMs[44] Research & Development Highlights - Amycretin is advancing to phase 3 development based on successful phase 1b/2a trial results, showing significant body weight loss[49, 53] - Semaglutide 2.4 mg demonstrated a 20% reduction in MACE in the SELECT trial for people with overweight or obesity and established CVD[249]